The Capitol LedgerEvery move in Congress, on the record
HomeBillsRecords

The Capitol Ledger

Built from the Congressional Record and Congress.gov. Every summary links to its source.

AboutFAQFeedbackTerms of ServicePrivacy Policy

Summaries are AI-generated from primary sources. Verify anything important against the original record.

The Capitol Ledger

Built from the Congressional Record and Congress.gov. Every summary links to its source.

The projectAboutFAQFeedback
LegalTerms of ServicePrivacy Policy

Summaries are AI-generated from primary sources. Verify anything important against the original record.

All bills
H.R. 2592·119th Congress·Introduced Apr 2, 2025

Aviation Medication Transparency Act of 2025

IntroducedTransportation and Public WorksSubstantive
View bill text
Sponsor
Rep. Casten, Sean [D-IL-6]
Committees
Transportation and Infrastructure Committee (primary)
Last action
Sep 15, 2026

Bottom line

This bill aims to enhance transparency and accessibility regarding FAA medical certification requirements for airmen by mandating the publication of an official, detailed, and regularly updated medication list.

What it actually does

This bill mandates that the Federal Aviation Administration (FAA) Administrator publish and maintain a comprehensive, publicly available list of medications and treatments approved for airmen to use for medical certification purposes. The list must be developed in consultation with key aviation stakeholders, include 'Do Not Issue' medications, specify stabilization periods, and be updated annually.

Proponents argue

Supporters argue this bill will bring much-needed clarity and reduce confusion for airmen and medical providers navigating the complex FAA medical certification process. By making the list public and comprehensive, it will streamline approvals, reduce delays, and ensure airmen can make informed decisions about their health and careers without fear of inadvertently violating regulations.

Opponents contend

Critics might argue that while transparency is generally beneficial, codifying a dynamic list in legislation could create rigidity or unintended consequences if updates are not timely or if the extensive consultation process becomes overly burdensome, potentially slowing down necessary medical policy adjustments.

The bill is very short and straightforward, making it highly accessible for any reader to understand its provisions quickly.

Section 2(a)

Requirement to Publish and Maintain an Approved Medication List

prominently featuredstraightforward

This provision mandates that the Federal Aviation Administration (FAA) Administrator must, within one year of the bill's enactment, publish and continuously maintain a list of medications and treatments that are considered safe for airmen to use while still being eligible for medical certification. This list must be made available on a public FAA website.

GroupImpactMechanismScale
GroupAirmen (pilots, air traffic controllers, etc.)ImpactIncreased clarity and accessibility of medical certification requirements, potentially reducing uncertainty and delays.MechanismPublicly available, comprehensive list.ScaleBroad impact on all airmen seeking or maintaining medical certification.
GroupMedical providers treating airmenImpactImproved guidance for prescribing medications that align with FAA regulations, reducing the risk of prescribing prohibited substances.MechanismDirect access to the official FAA list.ScaleSignificant for medical professionals specializing in aviation medicine.
GroupFederal Aviation Administration (FAA)ImpactIncreased administrative burden for compiling, publishing, and maintaining the list, but potentially reduced inquiries and appeals related to medication eligibility.MechanismMandated publication and consultation process.ScaleModerate administrative impact.

Supporters argue

Supporters argue that a publicly available, comprehensive list will demystify the FAA's medical certification process, empowering airmen and their doctors with clear, official guidance. This transparency will reduce the current reliance on informal channels or potentially outdated information, leading to more efficient and consistent medical certifications.

Critics contend

Some might argue that the FAA already provides guidance through various channels, and a rigid, legislatively mandated list might be difficult to keep current with rapidly evolving medical science and pharmaceutical developments. This could lead to a list that is quickly outdated or requires frequent, potentially slow, legislative updates.

Tradeoffs

The bill balances the need for transparency and clarity for airmen with the administrative burden and potential inflexibility of maintaining a dynamic medical list under a legislative mandate. There's a tension between providing definitive guidance and allowing for the necessary agility in medical policy.

Section 2(b)

Content and Consultation Requirements for the Medication List

prominently featuredstraightforward

This section details the specific requirements for the medication list. It mandates consultation with key aviation stakeholders, including the Aeromedical Innovation and Modernization Working Group, air traffic controller representatives, and airline pilot organizations. The list must be comprehensive, user-friendly, provided to new airmen, indicate stabilization periods for approved medications, include 'Do Not Issue' medications, offer a contact mechanism for medical providers, and explain why certain medications are allowed or prohibited.

Section 2(c)

Annual Update of the Medication List

mentioned in summarystraightforward

This provision mandates that the FAA Administrator must update the published medication list annually, starting one year after its initial publication. This ensures the list remains current and reflects the latest medical knowledge and pharmaceutical developments.

About this analysis. AI-Generated from the official bill text and available committee reports. Gaps in available data are noted explicitly. Verify important details with the official Congress.gov record.

On this page

  • Executive summary
  • Key provisions
  • Follow the money
  • Critical analysis
  • Questions to ask